• admin@ataxiatelangiectasia.es
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News

Bibliography

  • Hepatic veno-occlusive disease in ataxia-telangiectasia
    Hits: 767
    • United States of America
    • J Pediatr
    • liver disease
    • 1999
    • Srisirirojanakorn N
    • Finegold MJ
    • Gopalakrishna GS
    • Klish WJ
    Case Reports
     
     
    1999 Jun;134(6):786-8.
     doi: 10.1016/s0022-3476(99)70301-x.

    Hepatic veno-occlusive disease in ataxia-telangiectasia

    N Srisirirojanakorn1, M J Finegold, G S Gopalakrishna, W J Klish
    Affiliations 
      • PMID: 10356154
     
    • DOI: 10.1016/s0022-3476(99)70301-x

    Abstract

    Existing descriptions of liver abnormalities in ataxia-telangiectasia have been associated with co-existent hepatitis virus infection. Here we report veno-occlusive disease of the liver in 2 patients with ataxia telangiectasia that is not attributable to bone marrow transplantation or coincidental hepatitis infection.

  • Ocular Telangiectasia and Cerebellar Atrophy in Ataxia-Telangiectasia (Louis-Bar Syndrome)
    Hits: 846
    • DNA repair
    • malignancies
    • Tremor Other Hyperkinet Mov (N Y)
    • Cerebellar atrophy
    • Austria
    • 2025
    • Gattermeyer-Kell L
    • Kern D
    • Kögi M
    • Schwingenschuh P
    • ocular telangiectasias
    Case Reports
     
     
    . 2025 Jan 20:15:4.
     doi: 10.5334/tohm.992. eCollection 2025.

    Ocular Telangiectasia and Cerebellar Atrophy in Ataxia-Telangiectasia (Louis-Bar Syndrome)

    Lukas Gattermeyer-Kell1, Daniela Kern1, Mariella Kögl1, Petra Schwingenschuh1
    Affiliations 
      • PMID: 39867503
     
      • PMCID: PMC11758811
     
    • DOI: 10.5334/tohm.992

    Ask Copilot: Save time, read 10X faster with AI

    Abstract

    Background: Ataxia-telangiectasia (Louis-Bar syndrome) is a rare genetic disorder characterized by progressive ataxia, ocular telangiectasias, immunodeficiency and increased cancer risk due to impaired DNA repair.

    Phenomenology shown: Thorough clinical and subsequently radiological examination in a 19-year-old woman with a history of previously undiagnosed, progressive gait ataxia since early childhood, diffuse large B-cell lymphoma and severe combined immunodeficiency revealed the eponymous features of the disease, ocular telangiectasias and cerebellar atrophy, enabling targeted genetic testing.

    Educational value: Ocular telangiectasias represent an important clue for a diagnosis of ataxia-telangiectasia in young patients with progressive ataxia, implicating awareness of increased malignancy risk and treatment of immunodeficiency.

    Highlights: Ataxia-telangiectasia is a rare genetic disorder characterized by its eponymous features, progressive cerebellar ataxia and ocular telangiectasias. These signs can help in establishing an early diagnosis, hence preventing, or addressing secondary complications of the disease caused by impaired DNA repair, such as malignancies, immunodeficiency, and increased radiation sensitivity.

    Keywords: Ataxia-telangiectasia; DNA repair; Louis-Bar syndrome; cerebellar atrophy; malignancies; ocular telangiectasias.

  • Biomarkers in Ataxia-Telangiectasia: a Systematic Review
    Hits: 977
    • Schubert R
    • Germany
    • United Kingdom
    • Italy
    • Neurodegeneration
    • Biagiotti S
    • Van Os NJH
    • Willemsen MAAP
    • Australia
    • Clinical trial
    • Prayle AP
    • review
    • biomarker
    • J Neurol
    • Hensiek AE
    • Jeggo P
    • Coman D
    • Horvath R
    • Tiet MY
    • Donath H
    Review
     
     
    . 2025 Jan 15;272(2):110.
     doi: 10.1007/s00415-024-12766-7.

    Biomarkers in Ataxia-Telangiectasia: a Systematic Review

    M Y Tiet1, B-I Guțu1, P Springall-Jeggo2, D Coman3, M Willemsen4, N Van Os4, M Doria5, H Donath6, R Schubert6, R A Dineen78, S Biagiotti9, A P Prayle810, A T Biomarker Working Group, A E Hensiek1, R Horvathrh732@medschl.cam.ac.uk.">11
    Affiliations 
      • PMID: 39812834
     
      • PMCID: PMC11735505
     
    • DOI: 10.1007/s00415-024-12766-7

    Abstract

    Ataxia-Telangiectasia (A-T) is a very rare multisystem disease of DNA repair, associated with progressive disabling neurological symptoms, respiratory failure, immunodeficiency and cancer predisposition, leading to premature death. There are no curative treatments available for A-T but clinical trials have begun. A major limiting factor in effectively evaluating therapies for A-T is the lack of suitable outcome measures and biomarkers. We have performed a systematic review to collect the information currently available on biomarkers for A-T both in patients and preclinical studies. We have identified 56 reports discussing potential A-T biomarkers in both pre-clinical models and patients. These studies report on diagnostic biomarkers but prognostic biomarkers and responsive markers of clinical status are currently lacking. Some biomarkers of neurodegeneration in A-T show promise, including non-invasive neuroimaging biomarkers. Some biomarkers of oxidative stress and responsive markers to radiotherapy and steroid treatment have potential value in clinical trials. The formation of the A-T biomarker working group with international experts is an important step forward to facilitate the sharing of materials, data and expertise with the common goal of finding effective biomarkers for A-T.

    Keywords: Ataxia-Telangiectasia; Biomarkers; Clinical trials; Neurodegeneration.

  • Novel pathogenic ATM mutation with ataxia-telangiectasia in a Chinese family
    Hits: 850
    • China
    • ATM gene
    • case
    • Alpha-fetoprotein
    • immunodeficiency
    • Cerebellar atrophy
    • Front Genet
    • 2024
    • AFP
    • frameshift mutation
    • muscle atrophy
    Case Reports
     
     
    . 2024 Nov 28:15:1491649.
     doi: 10.3389/fgene.2024.1491649. eCollection 2024.

    Novel pathogenic ATM mutation with ataxia-telangiectasia in a Chinese family

    Qiaomin Zhou1, Minling Chen2, Enfu Tao3
    Affiliations 
      • PMID: 39678378
     
      • PMCID: PMC11638744
     
    • DOI: 10.3389/fgene.2024.1491649

    Abstract

    Ataxia-Telangiectasia (A-T) is a rare, autosomal recessive disorder characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, and increased cancer risk. Mutations in the ATM gene, which is essential for DNA damage repair, underlie this condition. This study reports a novel homozygous frameshift mutation (ATM_ex20 c.3062delT, p. Val1021fs) in a Chinese family with two affected siblings. The mutation, located in exon 20, has not been previously documented, expanding the spectrum of ATM mutations. The proband and her older sister presented with classic A-T symptoms, including gait instability and conjunctival telangiectasia. Both siblings presented with immunodeficiency, characterized by low immunoglobulin A (IgA) levels, slightly elevated IgM levels, and elevated alpha-fetoprotein (AFP). Cranial magnetic resonance imaging (MRI) findings revealed cerebellar atrophy and cerebral white matter lesions in both sisters. Interestingly, while both sisters shared the same mutation, their clinical severity differed, highlighting the complexity of genotype-phenotype correlations in A-T. The parents and an unaffected sister were heterozygous carriers, consistent with autosomal recessive inheritance. This study underscores the importance of genetic testing in A-T diagnosis and provides new insights into the genetic diversity of ATM-related diseases. Further research is needed to understand the broader implications of this mutation.

    Keywords: ATM gene; alpha-fetoprotein; ataxia-telangiectasia; cerebellar atrophy; frameshift mutation; immunodeficiency; muscle atrophy.

    Copyright © 2024 Zhou, Chen and Tao.

  • Rubella virus vaccine-induced granulomas: a case in children with ataxia-telangiectasia
    Hits: 715
    • granulomas
    • France
    • immunodeficiency
    • 2024
    • Le Lay F
    • Dompmartin A
    • Dermatol Reports
    • rubella
    • vaccine
    • Deparis M
    • Fraitag S
    Case Reports
     
     
    . 2024 Apr 11;16(4):9864.
     doi: 10.4081/dr.2024.9864. eCollection 2024 Nov 21.

    Rubella virus vaccine-induced granulomas: a case in children with ataxia-telangiectasia

    Florine Le Lay1, Marianna Deparis2, Sylvie Fraitag3, Anne Dompmartin1
    Affiliations 
      • PMID: 39669881
     
      • PMCID: PMC11635345
     
    • DOI: 10.4081/dr.2024.9864

    Abstract

    Ataxia telangiectasia (AT) is a rare autosomal recessive primary immunodeficiency disorder (PID) resulting from a mutation in the ATM gene involved in DNA repair. We describe the case of a young girl with cutaneous granulomas that developed after childhood vaccinations. Immunohistochemistry revealed granulomas induced by the rubella virus vaccine. This finding raises the question of the safety of live rubella vaccine strains in immunocompromised children.

    Keywords: ataxia telangiectasia; granuloma; immunodeficiency; rubella; vaccine.

  • Pioglitazone as a Possible Treatment for Ataxia-Telangiectasia
    Hits: 719
    • United States of America
    • review
    • Treatment
    • 2024
    • Pioglitazone
    • Shackelford R
    • Biomolecules
    • glutathione
    • iron-sulfur complex
    Review
     
    . 2024 Oct 8;14(10):1264.

     doi: 10.3390/biom14101264.

    Pioglitazone as a Possible Treatment for Ataxia-Telangiectasia

    Rodney Shackelford1
    Affiliations 
      • PMID: 39456197
     
      • PMCID: PMC11506080
     
    • DOI: 10.3390/biom14101264

    Abstract

    Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder characterized by immunodeficiency, progressive cerebellar ataxia, and an increased malignancy risk. Cells derived from individuals with AT show multiple defects, including high oxidant and ionizing radiation sensitivities, poor DNA repair, low iron-sulfur cluster levels, and low reduced glutathione. The clinical course of AT is progressive and unrelenting, with most individuals having a survival time of approximately twenty-five years. Presently, AT has no effective treatments, and most patients receive supportive care only. Recently, pioglitazone, a thiazolidinedione class used to treat type 2 diabetes, has been demonstrated to exert beneficial effects on AT cells and on diabetic individuals with AT. Here, I will discuss the possible molecular mechanisms of pioglitazone's favorable effects on the AT phenotype and why it may have utility in treating some aspects of AT.

    Keywords: ataxia-telangiectasia; glutathione; iron–sulfur complex; pioglitazone.

  • Ataxia telangiectasia SPN
    Hits: 950
    • United States of America
    • neurocutaneous syndromes
    • review
    • Semin Pediatr Neurol
    • 2024
    Review
     
     
    . 2024 Dec:52:101169.
     doi: 10.1016/j.spen.2024.101169. Epub 2024 Nov 19.

    Ataxia telangiectasia

    John Collyerjohn.collyer@chp.edu.">1, Deepa S Rajanrajands@upmc.edu.">2
    Affiliations 
      • PMID: 39622612
     
    • DOI: 10.1016/j.spen.2024.101169

    Abstract

    Ataxia telangiectasia (AT) is a rare neurocutaneous syndrome that results from biallelic pathogenic variants in the ataxia telangiectasia mutated (ATM) gene, named for its characteristic cerebellar ataxia in the early toddler years and variable oculocutaneous telangiectasias in the school age years. While its name only hints at neurologic and cutaneous manifestations, this multisystemic disorder also has important immunologic, oncologic, respiratory, and endocrinologic implications. This article will review the function of the ATM gene, the neurologic manifestations of AT, non-neurologic complications, mimickers of AT (including other disorders of defective DNA repair), and the realm of therapeutic research for AT.

    Keywords: Ataxia; Ataxia telangiectasia; Neurocutaneous disorder.

  • Dietary intakes and nutritional issues in inborn errors of immunity: a systematic review
    Hits: 897
    • primary immunodeficiency
    • Front Immunol
    • Nutritional
    • Nutritional status
    • 2024
    • Freer M
    • Pursey KM
    • Bhatia R
    • Preece K
     
    . 2024 Sep 27:15:1408985.
     doi: 10.3389/fimmu.2024.1408985. eCollection 2024.

    Dietary intakes and nutritional issues in inborn errors of immunity: a systematic review

    Macey Freer1, Rani Bhatia23, Kahn Preece23, Kirrilly M Pursey145
    Affiliations 
      • PMID: 39399505
     
      • PMCID: PMC11466791
     
    • DOI: 10.3389/fimmu.2024.1408985

    Abstract

    Introduction: Inborn errors of immunity (IEI) are characterized by an inherited dysregulation or absence of immune system components that can manifest clinically in complications that predispose an individual to feeding difficulties or impaired swallowing, digestion, and absorption. Treatment side-effects or altered requirements may further impair nutritional status. While adequate nutrition is necessary for optimal growth and immune function, little is known about nutritional intakes in IEI, and best practice nutrition guidelines are limited. This review aimed to synthesize current evidence on the dietary intakes, anthropometry and nutritional biochemistry in individuals with an IEI.

    Methods: A systematic review of literature published from database inception to March 2023 was conducted in accordance with the PRISMA guidelines. Articles eligible for inclusion reported anthropometric, biochemical, or dietary intake-related measures in pediatric or adult patients with a diagnosed IEI. Identified articles were screened for eligibility; data was synthesized descriptively.

    Results: A total of 4488 studies were retrieved of which 34 were included. Across studies, 2894 IEI individuals were included (age range 4 weeks to 83y), predominantly focusing on ataxia telangiectasia (AT) and common variable immunodeficiency (CVID). A significant association between inadequate energy intakes and IEI was identified (n=6 studies); however, there was significant variability in adequacy of macro- and micronutrients across studies. Patients with IEI were at risk of malnutrition (range 30% to 70%); although anthropometric assessment measures were not consistent across studies. Biochemical assessments found patients were also at risk of micronutrient deficiencies including vitamin D.

    Discussion: This review identified few studies assessing dietary intakes, anthropometry and nutritional biochemistry in patients with IEI, with considerable heterogeneity across studies. Future longitudinal studies using consistent validated dietary assessment tools and anthropometric measures in diverse IEI patient populations are needed. This review reinforces the need for dietetic input in people with an IEI and the development evidence-based clinical practice guidelines for people with an IEI.

    Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023412365.

    Keywords: dietary intake; inborn errors of immunity; nutritional issues; nutritional status; primary immunodeficiency.

  • The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review
    Hits: 937
    • United States of America
    • Iran
    • dexamethasone
    • Erythocyte delivery
    • Cerebellum
    • gene therapy
    • N-acetyl-leucine
    • 2024
    • Mehri A
    • Toosi MB
    • Tavasoli AR
    • Saberi-Karimian M
    Review
     
     
    . 2024 Dec;23(6):2607-2615.
     doi: 10.1007/s12311-024-01746-2. Epub 2024 Sep 27.

    The Latest Developments for the Treatment of Ataxia Telangiectasia: A Narrative Review

    Ali Mehri1, Mehran Beiraghi Toosi2, Ali Reza Tavasoli34, Maryam Saberi-Karimiansaberikm@mums.ac.ir.">5saberikm@mums.ac.ir.">6saberikm@mums.ac.ir.">7
    Affiliations 
      • PMID: 39327359
     
    • DOI: 10.1007/s12311-024-01746-2

    Abstract

    Ataxia telangiectasia (AT), Louis-Bar syndrome, is a rare neurodegenerative disorder caused by autosomal recessive biallelic mutations within the ataxia telangiectasia mutated (ATM) gene. Currently, there are no curative therapies available for this disorder. This review provides an overview of the latest advances in treatment methods including 1- Acetyl-DL-leucine, 2- Bone Marrow Transplantation, 3- Gene Therapy, 4- Dexamethasone, and finally 5- Red Blood Cells (RBCs) as a carrier for dexamethasone (encapsulation of dexamethasone sodium phosphate into autologous erythrocytes, known as EryDex). Most of the treatments under investigation are in the early stages, except for the EryDex System. It appears that the EryDex system and N-Acetyl-DL-Leucine may hold promise as potential treatment options.

    Keywords: Ataxia telangiectasia; Dexamethasone; Erythrocyte delivery; Gene therapy; N-acetyl-DL-leucine.

  • Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders
    Hits: 903
    • review
    • Clin Cancer Res
    • Walsh MF
    • 2024
    • Nakano Y
    • Cancer screening
    • genomic instability
    Review
     
     
    . 2024 Nov 15;30(22):5009-5020.
     doi: 10.1158/1078-0432.CCR-24-1098.

    Update on Recommendations for Cancer Screening and Surveillance in Children with Genomic Instability Disorders

    Yoshiko Nakano1, Roland P Kuiper2, Kim E Nichols3, Christopher C Porter4, Harry Lesmana5, Julia Meade6, Christian P Kratz7, Lucy A Godley8, Luke D Maese9, Maria Isabel Achatz10, Payal P Khincha11, Sharon A Savage11, Andrea S Doria12, Mary-Louise C Greer12, Vivian Y Chang13, Lisa L Wang14, Sharon E Plon15, Michael F Walsh16
    Affiliations 
      • PMID: 39264246
      • PMCID: PMC11705613
    • DOI: 10.1158/1078-0432.CCR-24-1098

    Abstract

    Genomic instability disorders are characterized by DNA or chromosomal instability, resulting in various clinical manifestations, including developmental anomalies, immunodeficiency, and increased risk of developing cancers beginning in childhood. Many of these genomic instability disorders also present with exquisite sensitivity to anticancer treatments such as ionizing radiation and chemotherapy, which may further increase the risk of second cancers. In July 2023, the American Association for Cancer Research held the second Childhood Cancer Predisposition Workshop, where multidisciplinary international experts discussed, reviewed, and updated recommendations for children with cancer predisposition syndromes. This article discusses childhood cancer risks and surveillance recommendations for the group of genomic instability disorders with predominantly recessive inheritance, including the DNA repair disorders ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi anemia, xeroderma pigmentosum, Bloom syndrome, and Rothmund-Thomson syndrome, as well as the telomere biology disorders and mosaic variegated aneuploidy. Recognition of children with genomic instability disorders is important in order to make the proper diagnosis, enable genetic counseling, and inform cancer screening, cancer risk reduction, and choice of anticancer therapy.

Page 41 of 42

  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42

Language

Select your language

  • Hindi (India)
  • Hebrew
  • Arabic (اللغة العربية)
  • Turkish (Turkey)
  • 日本語 (Japan)
  • Russian (Russia)
  • Français (France)
  • Deutsch (Deutschland)
  • Español (España)
  • Nederlands (nl-NL)
  • Português Brasileiro (pt-BR)
  • Polski (PL)
  • Italiano (Italia)
  • English (United Kingdom)

Tweets by A_Tinfo

  • Sitemap
Ataxia Telangiectasia
  • Home
  • Bibliography
    • Authors
    • Cells and molecules
    • Clinical
    • Country
    • Diseases
    • Drugs
    • Experimental
    • Journals
    • Methods
    • Year
  • Resources
  • What is A-T?
  • News
  • admin@ataxiatelangiectasia.es